Cytokinetics (CYTK) Misses Q4 EPS by 24c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $73.62 --0%
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ANAB, ANIX, MNY, More
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 EPS of ($1.45), $0.24 worse than the analyst estimate of ($1.21). Revenue for the quarter came in at $1.96 million versus the consensus estimate of $7.45 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
- KeyBanc Starts Dow Inc. (DOW) at Sector Weight
- RH (RH) Tops Q2 EPS by $2.31
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
